Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of TRC003 injection in PSMA-positive metastatic castration-resistant prostate cancer
CTR20260770Phase 2Active
- Sponsor
- C Ray Therapeutics
- Start
- May 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TRC003 in prostate cancer (PCa), sponsored by C Ray Therapeutics. Started May 2026; status: active.
02
Drugs
TRC003
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20260770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260770.